MannKind | MNKD - Operating Expenses

Stock Price
5.68
Daily Change
0.11 1.89%
Monthly
1.70%
Yearly
-0.44%
Q1 Forecast
5.37

MannKind reported $63.35M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Adma Biologics USD 83.21M 4.02M Sep/2025
BioCryst Pharmaceuticals USD -387.89M 33.7M Sep/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Halozyme Therapeutics USD 211.07M 74.73M Dec/2025
Insmed USD 513.55M 109.86M Dec/2025
Karyopharm Therapeutics USD 61.82M 3.24M Dec/2024
MacroGenics USD 67M 8M Sep/2025
MannKind USD 63.35M 2.51M Sep/2025
Merck USD 10.16B 558M Dec/2025
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Novavax USD 218.53M 34.86M Sep/2024
Novo Nordisk DKK 6.5B 32.8B Jun/2025
Pfizer USD 12.91B 79.89B Dec/2025
Sanofi EUR 10.51B 1.21B Dec/2025
Xencor USD 68.52M 8.26M Sep/2025